HanYu Pharmaceuticals: signed a joint development agreement with Shenzhen Carbon Cloud Smart Peptide Pharmaceutical Technology Co., Ltd. for the innovative peptide drug "GLP-1R/GIPR/GCGR triple agonist".

HanYu Pharmaceuticals announced that the company has signed a "GLP-1R/GIPR/GCGR Triple Agonist Peptide Innovative Drug Joint Development Agreement" with Shenzhen TanYun Smart Peptide Drug Technology Co., Ltd. Both parties will collaborate on the development of innovative peptide drugs for the treatment of metabolic diseases such as weight control. According to the agreement, HanYu Pharmaceuticals will be responsible for preclinical research, IND application, clinical trials, and product registration, and will bear the corresponding costs. TanYun Smart Peptide will be responsible for molecular screening and will bear all development costs during the screening process. HanYu Pharmaceuticals will pay TanYun Smart Peptide a maximum of 38 million yuan in milestone payments at key project milestones. After the product is approved for market sale in the future, HanYu Pharmaceuticals will pay TanYun Smart Peptide a profit share of no more than 10% or 3% based on sales revenue. This cooperation will help enhance the company's innovative capabilities and product diversity in the field of metabolic disease treatment.